Skip to main content

Table 2 Results of log-rank tests

From: Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

Factor 4-year bRFS (%) (95% CI) p value
Pathologic tumor stage   < 0.001
T1-2 79.2 (66.0-92.3)  
T3-4 31.7 (17.0-46.4)  
Surgical margin   0.652
Positive 48.6 (32.0-65.1)  
Negative 57.1 (42.7-71.4)  
Gleason score   0.189
≤ 7 58.9 (44.5-73.3)  
≥ 8 35.2 (14.7-51.5)  
Preoperative PSA (ng/ml)   0.037
< 10 62.0 (47.7-76.3)  
≥ 10 39.3 (22.5-56.0)  
Pre-RT PSA (ng/ml)   0.620
< 0.25 54.5 (37.5-71.6)  
≥ 0.25 45.9 (30.2-64.9)  
PSA doubling time (months)   0.059
< 7 34.6 (17.5-51.8)  
≥ 7 62.2 (46.7-77.7)  
RT dose (Gy)   0.068
< 64 36.8 (15.2-58.5)  
≥ 64 51.7 (37.6-65.9)  
BED (Gy) (α/β = 1.5)   0.213
< 145 41.4 (23.5-59.3)  
≥ 145 54.3 (39.5-69.1)  
Time from RP to RT (months)   0.310
< 24 45.2 (29.1-61.4)  
≥ 24 57.4 (40.9-73.9)  
Hormone therapy   0.627
Done 50.5 (20.2-72.9)  
Not done 50.7 (37.6-63.7)  
  1. Abbreviations: bRFS = biochemical relapse-free survival, RT = radiotherapy, PSA = prostate-specific antigen, BED = biological effective dose, RP = radical prostatectomy, CI = confidence interval